

# Index

- AAV (adeno-associated virus) 20, 46, 89, 217
- absorption 4, 46, 49–50, 52–53, 55–57, 60–61, 65, 72–73, 94, 96, 98, 106, 245
- absorption enhancers 45, 74, 79, 98–99
- ACE (angiotensin-converting enzyme) 196, 198, 206, 222, 228
- ACE inhibitors 199, 206
- activated protein C *see* APC
- acute lung injury *see* ALI
- acute respiratory distress syndrome *see* ARDS
- adeno-associated virus *see* AAV
- adhesion, leukocyte 154, 197
- aerodynamic diameters 78, 85–86
- aerosol particles 27, 74–75, 84
- aerosols 80, 84–86, 98, 102, 131, 194, 230, 250
- air pollution 248, 250–51
- airway cells 4, 13
- airway cilia 73
- airway diseases 11, 87, 124, 244–45, 247
- chronic obstructive 4, 6
- airway epithelial cells 213, 215, 240
- airway epithelium 70, 72, 86, 88, 232, 239, 242–43, 250, 253
- airway fibrosis 264
- airway gene delivery 215–16
- airway hyperreactivity 136, 138, 158–59, 162, 165, 186
- airway inflammation 137–38, 161, 190, 237, 240, 242, 251
- airway lumen 71–72
- airways
- asthmatic 138, 162, 243
- lower 182
- ALI (acute lung injury) 11, 117–18, 196–97, 219, 222
- allergens 136, 138, 143, 157, 177, 185–86, 243, 264–65
- allergic asthma 11, 135–36, 155, 160, 166, 184, 186, 188
- murine model of 246–47, 271
- allergic diseases 142, 162, 186–87, 192, 236
- allergic response 139, 265, 272
- allergy 3, 8, 50, 135–36, 138, 140, 142, 144, 146, 148, 156–58, 160, 164, 185, 192
- alveolar cells 69–70
- alveolar epithelium 71–73
- alveolar macrophages 2–4, 71, 73, 86, 188, 244, 263
- alveoli 2, 27, 70
- amine groups 205, 216–17
- amino groups 170–71
- aminopeptidases 52, 57, 224
- angiotensin-converting enzyme *see* ACE
- antibodies 18–19, 24–25, 77–78, 91–92, 109–10, 112, 116, 145, 148–49, 151–52, 155, 168, 209–10, 216, 220
- anti-TM 200, 214–15
- antigen-presenting cells 143, 265
- antigens 87, 97, 109, 112, 136, 143–45, 151, 157–59
- antitumor activity 20, 37
- APC (activated protein C) 201, 207, 225
- aptamers 13, 107, 145, 152–53, 165, 199
- ARDS (acute respiratory distress syndrome) 76, 117–18, 131
- asthma 3–4, 135–37, 139–44, 146–47, 155–57, 159–62, 164–65, 184–85, 187–88, 235–39, 242–44, 246–48, 250–55, 263, 265–66

- atopic 137, 156, 163–64, 271
- murine model of 141, 164
- pathogenesis of 136–39, 242, 255
- treatment of 11, 136, 138–40, 156, 183–84, 219, 251, 253, 266
- asthma exacerbations 240
- atopic asthmatics 136–37, 255
- autoimmune diseases 138, 148
  
- barriers, cellular 193, 199, 201, 205, 219
- blood 7, 72, 108–9, 120, 178–79, 181, 194, 200, 221, 228–29
- blood glucose levels 59, 79, 81
- body fluids 108–9, 117
- breast cancers, metastatic 22
- bronchi 1–2, 70
- bronchitis, chronic 2–3
- bronchoalveolar lavage 163, 165, 179–80, 265
- bronchodilation 237–38
  
- cancer 8–9, 14–15, 17–19, 21, 27, 29, 34–35, 37–44, 91–92, 107, 118, 124, 127, 133, 162–65
  - hepatic 174–75
- cancer cells 18, 25–26, 28–29, 32, 35, 38, 43, 121, 226
  - breast 25, 39, 148
  - metastatic 121–22
- cancer therapy 9, 13, 16, 24, 35–36, 158, 163
- cancer treatment 36, 148
- carbon 24, 33, 131, 249
- carbon nanotubes *see* CNTs
  - multiwalled 24, 261, 271–72
- carboplatin 11, 20, 22, 37
- carcinogenesis 28–29, 42, 122
- catalase 75, 198, 220–22, 225, 228
- cationic lipids 88, 215, 231
- cationic liposomes 76, 88, 90–91, 188, 205, 212, 214, 218, 227
- caveolae 202–3, 226
- cell-penetrating peptides *see* CPPs
- cell proliferation 16, 30, 147, 153, 267
- cell surface molecules 146, 148, 196
- cells
  - goblet 48, 70–71, 73, 184
  - live 39, 127
  - mast 137, 238
- cellular uptake 151, 153, 199, 201
- cetuximab 17, 30–31, 33, 35, 43
- CFTR (cystic fibrosis transmembrane regulator) 10, 68, 88–89, 119
- chemokine receptor profiles, unique 154–55
- chemokine receptors 146, 155, 163–64
- chemokine receptors CCR4 163
- chemotherapy, aerosolized 27–28
- chitin 171, 188–89
- chitosan 11, 49, 59, 61, 64–66, 68, 90–91, 93, 96, 168–77, 179–83, 186, 188–91, 247, 250
  - thiolated 64, 68, 94, 191
- chitosan-DNA nanoparticles 183
  - oral 177
- chitosan-gene
  - Nanocomplexes 181
- chitosan gene therapy 177, 179
- chitosan IFN-gamma-pDNA nanoparticle *see* CIN
- chitosan nanoparticle
  - applications 183
- chitosan nanoparticle applications to treat allergic disease, examples of 183
- chitosan nanoparticles 67–68, 99, 168–69, 175–77, 179, 181, 183–86, 192
  - crosslinked 97
  - developed modified 175
  - insulin-loaded 64
  - insulin-loaded thiolated 64

- insulin-loaded unmodified 64
- loaded 161
- thiolated 64, 184
- unmodified 64
- chitosan nanospheres 247
- chitosan-reduced gold nanoparticles 64–65
- chitosan solution 64, 181–82
- chitosan use 170–71
- chronic obstructive lung diseases 1–2, 4, 6–12, 14, 244, 252
- chronic obstructive pulmonary disease *see* COPD
- cigarette smoke *see* CS
- CIN (chitosan IFN- $\gamma$ -pDNA nanoparticle) 11, 178, 183–84, 188
- CIN treatment 184
- clathrin-mediated endocytosis *see* CME
- CME (clathrin-mediated endocytosis) 202
- CNTs (carbon nanotubes) 24, 42, 103–4, 107, 112, 122, 128, 130, 260–69, 272–73
- columnar cells 48, 71
  - ciliated 48, 70, 72
- complexes, pDNA/chitosan 176
- conjugates, nanoparticle–peptide 225
- conjugation of nanoparticles 153–54
- contrast agents 22, 24–25, 34, 114, 168, 197
- COPD (chronic obstructive pulmonary disease) 2–6, 10–12, 87, 135, 156, 182, 194, 235–38, 240–42, 244, 246, 248, 250–52, 254, 259
- CPPs (cell-penetrating peptides) 92, 94, 161, 201
- CS (cigarette smoke) 2, 4, 6, 10, 202, 241, 244, 254–55
- cyclodextrins 38, 55–56, 74, 81, 169
- cystic fibrosis 3, 11–12, 14, 68, 76, 87–88, 91, 97, 100, 118–19, 132
- cystic fibrosis transmembrane regulator *see* CFTR
- cytokines 71, 87, 129, 137–40, 142–43, 145, 150, 155, 163, 182, 239
- DCs (dendritic cells) 73, 86, 136–37, 143, 148, 150, 175–76
- DDS *see* drug delivery system
- defensins 240, 254
- degradable starch microspheres *see* DSM
- delivery
  - intranasal 92, 95
  - protein 208, 210
- delivery systems 57, 61, 65, 70, 199–201, 203–5
  - nano-based drug 4, 6, 260
  - nasal 62, 64, 94, 96, 182, 191
- delivery vehicles 200
- dendritic cells *see* DCs
- diagnostics 1, 15, 45, 103–4, 108, 112, 123–24, 132, 135, 159, 167, 193, 199, 206, 235
  - combined delivery of 8
- diatrizoic acid nanoparticle agglomerates 115, 131
- DNA 18, 29, 33, 44, 107, 176, 183, 205, 213–14, 216, 228
- DNA damage 28, 32–33, 260, 267–68, 272
- DNA nanoparticles 99, 183, 191
  - delivered 175
  - stable PEGylated poly-L-lysine 232
- DNA repair 33, 44
- downstream effector cells 139
- DPPC-liposomes 63
- drug absorption 50, 53, 72–73, 93
- drug delivery 6, 17, 23, 36, 40, 92–93, 98, 105, 169, 187, 194–95, 203, 259–60, 263–64, 269
  - controlled 4, 6
  - intranasal 93–94, 124
  - nanoparticle 152

- nanoparticle-mediated 4
- targeted 7, 20, 36, 62, 199
- drug delivery platforms 260, 262, 269
- drug delivery system (DDS) 4–6, 8, 10, 21, 23–24, 57, 62–63, 93, 98, 141, 210, 228, 256, 260
- drug delivery systems 8, 10, 21, 24, 57, 228, 256, 260
- drug/gene delivery, targeted 7, 9
- drugs
  - liposomal 23
  - peptide 57, 59–60, 63, 65, 94
  - protein 52, 57, 59
- dry powder inhalers 70, 74–75, 82–83, 85, 100
- DSM (Degradable starch microspheres) 65–66, 96
- dye-doped silica/ORMOsil nanoparticles 106, 110
  
- EC Markers 196–98
- EC surface molecules 206
- ECs (endothelial cells) 154, 194–95, 197–203, 210–11, 215–16, 218, 221–23, 229
- EGFR (epidermal growth factor receptor) 15–17, 19, 30–32, 35, 148, 239, 251, 255
- EGFR overexpressing cancer cells 30, 33
- EGFR-targeted hybrid plasmonic magnetic multifunctional nanoparticles 29, 31, 33
- EGFR-targeted hybrid plasmonic magnetic nanoparticles 30, 43
- EGFR-targeted nanoparticles 31–34
- ELISA (enzyme-linked immunosorbent assay) 105, 110, 117, 129, 178
- emphysema 2–3, 5, 10, 107
- endocytosis 11, 46, 188, 201–4, 211, 225–26
- receptor-mediated 31–32, 153–54, 176
- endosomal release 76, 204–5
- endothelial cells *see* ECs
  - mouse lung 102, 222, 231
- endothelium 73, 154, 200, 202, 208, 212, 218, 220, 222, 227
- engineered nanoparticles 122, 125, 269
- enzyme-linked immun- osorbent assay *see* ELISA
- enzymes 52, 57, 69, 71, 107, 110, 208, 210, 251
- eosinophils 137, 141, 158, 178, 180–81, 184, 186
- epidermal growth factor receptor *see* EGFR
- epithelial barrier 3, 238, 240, 242–44
- epithelial cells 50, 70, 147, 165, 216, 240, 243
  - alveolar 79, 99, 213
  - nasal 46–47
- epithelium 48, 58, 71–73, 94, 239–41, 243–44
- erlotinib 17, 30–31, 35
- exacerbations 135, 237, 249–51, 253, 260, 264–65, 271
  
- fibrosis 5, 101, 122, 262, 264, 267
- fragments, antigen-binding 149, 209
- fullerenes 24, 39, 260, 266
- fusion proteins 149, 209
  
- gels, novel chitosan 189
- gene delivery 3, 12, 67–68, 88, 90, 98, 125, 158, 176, 188, 190, 196–97, 212, 215–17, 226–27

- stable nanoparticle-mediated 5
- gene expression 38, 88, 90–91, 175, 216–17, 230–31, 240, 244
- gene therapy 22, 67, 76, 87, 89, 92, 124, 135, 175, 177, 207, 212, 227
  - nanoparticle-based cytokine 191
  - gene transfer 88, 175, 191, 212, 214, 218, 231–32
  - genes 6–7, 45–46, 67–69, 76, 82, 88–89, 91, 102, 125, 169, 175–77, 190, 194, 225, 230–33
  - tumor suppressor 33, 37
- GFP (green fluorescent protein) 68, 176
- glucocorticoid receptors *see* GR
- GNPs (gold nanoparticles) 25–26, 28–29, 33–34, 40, 42, 104–7, 111, 122, 127–28, 130, 148
- gold nanoparticles *see* GNPs
- GR (glucocorticoid receptors) 140
- green fluorescent protein (GFP) 68, 176
  
- hyaluronan 19–20
- hydrophilicity 49, 52–53, 73
  
- ICT (immuno-chromatography test) 120
- imaging agents 153, 161, 197–98, 200, 207, 260
- immune cells 144–45, 215
- immune responses 66, 68, 87–89, 92, 97, 100–1, 120, 137, 143–44, 148–49, 152–53, 239–42, 247, 265, 271–72
- immunization 67, 161, 186
- immuno-chromatography test *see* ICT
- immunoconjugates 196–97, 208–10
- immunogenicity 76, 87–88, 152, 157, 199, 248–49
- immunotargeting, vascular 208, 211, 220, 229
- immunotherapy 177, 185–86, 192
- inflammation 8, 10, 41–42, 68, 130–31, 141, 147, 161, 166, 187, 196, 237–38, 242, 249, 255
  - chronic 2, 42, 243
  - severe 4, 6–7
  - sites of 154–56, 209
- inflammatory cells 2, 4, 9, 141, 199, 207
- inflammatory genes, expression of 140
- inflammatory mediators 71, 74, 118
- inhalation 27–28, 37, 79, 85, 98, 122, 178, 181, 237, 240, 245, 261, 263–64, 266–67, 271
- inhaled nanoparticles 12, 77–78, 124
- inhibitors
  - protease 55, 57, 74, 98, 100
  - tyrosine kinase 15, 31
- insulin 10, 23, 56–61, 64–66, 72, 77, 79–81, 94–96, 98–100
  - absorption of 57–58, 61, 64–65
  - pulmonary absorption of 74, 81, 100
- insulin-containing chitosan nanoparticles 64
- integrins 19, 74, 146, 154, 221, 224
- intercellular adhesion molecule-1 198, 220–22
- intracellular delivery 154, 201–3, 229
- intranasal administration 54, 59, 61–68
- intratracheal instillation 87, 90–91, 262–63, 267, 270–71
- intravenous administration 88, 195, 212, 216, 230

- iron oxide nanoparticles 21, 25, 34, 39, 41, 104–5, 107, 114, 121
- leukocytes 150, 154–55, 196–97, 221
- Lewis lung cancer cells 75
- ligands 18–19, 30, 78, 124, 147, 198–200, 206, 208, 214, 216, 218–19, 224
  - natural polypeptide 153
- lipophilicity 49, 52–53, 73
- lipoplexes 212–14
- liposomal doxorubicin 21
- liposomes 9, 23, 47, 55, 57–58, 62, 66, 74–75, 81, 87–88, 95, 102, 200–1, 213, 232–33
  - charged 62
  - multilamellar 213–14
  - pH-sensitive 75
  - uncoated 62
- liver 23, 26–27, 52, 128, 141, 145, 216–19, 245
- localized surface plasmon resonance *see* LSPR
- LSPR (localized surface plasmon resonance) 107, 111
- lung cancer 3–4, 8, 11, 15–18, 20, 22, 26–28, 30–32, 34, 36, 42–44, 74, 76, 87–88, 121–22
  - diagnosis of 121
  - non-small-cell 16, 35
- lung cancer cells 17, 33, 98
- lung cancer patients 15, 17, 122
- lung cancer treatment 28, 90
- lung diseases, various 104
- lung disorders 116–17, 119, 121
  - examples of 116–17, 119, 121
- lung ECs 194, 197, 200, 202, 216, 218–19
- lung epithelial cells 154, 185
- lung fibroblasts 42, 266
- lungs 1–4, 68–73, 75–76, 84–86, 90–91, 101–5, 117–18, 121–23, 193–95, 206–11, 218, 224–26, 231–32, 260–62, 266–68
  - distal 175–76
- lymphocytes 87, 140–41, 156–57, 159, 164, 181, 186
- lysosomes 203, 211, 216
- macromolecular drugs 48–50, 56, 69
- macromolecules 45–48, 50, 52, 54, 56–58, 62, 64–66, 68–70, 72, 74, 82, 92, 96, 98, 204–5
  - delivery of 45, 56, 77, 82, 85, 92
  - pulmonary delivery of 76, 79
- macrophages 3–4, 6–7, 27, 73–74, 77, 137, 141, 143, 175–76, 181, 188, 215, 261–62, 266, 268
- magnetic nanoparticles 22, 25, 32, 112
- magnetic resonance imaging *see* MRI
- major histocompatibility complex *see* MHC
- mammalian cells 44, 202, 227, 232
- membranes, endosomal 203–5
- mesothelioma 262, 268
- metered-dose inhalers 74, 82–84, 86, 99
- MHC (major histocompatibility complex) 87, 145, 242
- micelles 74, 197, 246
- microemulsions 74, 79–80, 99
- microparticles 46, 55, 57, 65, 68, 76, 78, 87, 99, 108, 159, 195, 220
- microspheres 59, 66, 76, 94, 96, 182
- modifications, nanoparticle surface 145
- molecular imaging 6, 18, 115, 121, 124, 128
- molecular targets 13, 199, 201, 204–5
- molecular weight (MW) 46, 52, 72, 163, 169, 171, 205

- molecules, hydrophobic 74, 77  
 monoclonal antibodies 22, 129, 148, 152, 198, 238  
 MRI (magnetic resonance imaging) 13, 21, 25, 29–30, 34, 107, 114–15, 121, 131, 206  
 MTB (Mycobacterium TB) 119–21, 132  
 mucociliary clearance 50, 53–54, 65, 73, 86  
 mucus 2–3, 48, 50, 70, 72–73, 77, 89, 207, 264  
 mucus layer 2, 48–50, 70, 91  
 multifunctional nanoparticles 8–9, 15, 116, 167–68  
 MWCNTs *see* multiwalled carbon nanotubes  
 MW *see* molecular weight  
 MWCNTs (multiwalled carbon nanotubes) 261–68  
   inhaled 264, 266–68  
 mycobacterium TB *see* MTB
- nanodelivery systems, therapeutic efficacy of 4, 6  
 nanoliposomes 20, 37  
 nanomedicine 10–12, 15–16, 34, 38, 40, 98–99, 103, 124–25, 127, 131, 133, 156, 159, 168, 256–57  
 nanoparticle agents 15, 20–21, 23  
 nanoparticle agents for lung cancer 20  
 nanoparticle-based probes 106, 111, 115  
   photostable 118  
 nanoparticle delivery 145, 149, 153, 177  
   receptor-targeted 155  
   targeted 153  
 nanoparticle formulations 78  
   chitosan-based 175  
   insulin-loaded chitosan/tripolyphosphate 78  
   nanoparticle-mediated gene delivery 38, 256  
   nanoparticle platform, chitosan-based 144  
   nanoparticle surfaces 149, 154  
   nanoparticle technology application 187  
   nanoparticle tumor specificity 148  
   nanoparticle uptake 64, 67  
 nanoparticles 11–12, 16–19, 21–34, 36–43, 63–68, 76–81, 104–7, 122–28, 135–36, 140–42, 144–46, 152–54, 156, 164, 168–69  
   biodegradable 12, 160  
   chitosan/IFN- $\gamma$  pDNA 178  
   diagnostic 104  
   fluorescent 106, 113  
   inorganic 104–5, 122  
   insulin-loaded borohydride-reduced 65  
   insulin-loaded starch 64  
   insulin-PEG-g-chitosan 65  
   large porous PLGA insulin 77  
   ligand-coated 203  
   lipid-based 162, 233  
   liposomal 149  
   liposome-based 23  
   metallic 107, 111, 127  
   oligochitosan 176  
   paramagnetic 25  
   plasmonic 29  
   therapeutic 136  
   tumor-targeted 18  
   various nanomaterial-based 16, 18  
 nanophosphors 105–6  
 nanotechnology 1–2, 4, 6, 8, 12, 14–15, 17–18, 20–23, 27–28, 34–35, 39–40, 103–4, 123–24, 155–56, 167  
 nanotheranostics 7, 9, 12  
 nasal absorption 48, 50–52, 54, 56, 64, 93, 95–96  
 nasal cavity 1, 45, 47–48, 50, 52–55, 59–61, 65–66, 93, 182

- nasal delivery 46, 64–65, 93, 95–97
- nasal delivery of vaccines 66–67
- nasal drug delivery 46–47, 49, 51, 53, 55, 59, 61, 63, 65, 67, 95–96, 219
- nasal mucosa 46–50, 52–57, 60–66, 68, 93, 182
- nasal secretion 50, 52–53
- nasal sprays 55, 59–60
- natriuretic peptide receptor A *see* NPRA
- nebulizers 74–75, 82, 84, 87, 244
- neutrophils 4, 7, 141, 150, 180–81, 186, 239
- non-small-cell lung cancer *see* NSCLC
- noninvasive pulmonary delivery of nanoparticles 77
- nose 1, 47–48, 55, 93
- nostrils 48, 54, 59
- NPRA (natriuretic peptide receptor A) 181, 190
- NSCLC (non-small-cell lung cancer) 16, 27–28, 30–31, 35, 43, 74
- NSCLC, advanced 22
- obstructive lung diseases 3–6, 235–39, 241, 243, 246, 250, 264
- oligonucleotides 91, 110–11, 159, 205, 212, 214, 230, 232
- antisense 76, 91–92, 98, 102, 214, 231
- optical imaging 13–14, 30, 40, 113–14
- ovalbumin 62, 144, 164, 264–65
- oxidative stress 2, 10, 28, 32, 42, 119, 196, 208, 220–21, 249, 256, 267, 271
- PAMPs *see* pathogen-associated molecular patterns particles inhaled 73, 86, 99, 261
- viral 204, 218
- pathogen-associated molecular patterns (PAMPs) 143
- pathogenesis 1, 3, 135, 155–56, 212, 243, 255, 262
- PBS (phosphate-buffered saline) 63, 181
- PCP (pneumocystis pneumonia) 118
- PDGF (platelet-derived growth factor) 262, 265–66
- PEI (polyethylenimine) 77, 78, 89–91, 99, 147, 169, 205, 216–17, 232–33
- peptidase 55, 57
- peptide ligands 198
- peptides 18, 45, 49, 52, 57, 59, 61, 65, 69, 73, 78, 81, 84, 107, 153
- phosphate-buffered saline *see* PBS
- physical nanoparticle cross-linker 144
- plasmid DNA 68, 76, 78, 150, 161, 177, 200, 214, 216, 218, 227–28, 231–32, 247
- platelet-derived growth factor *see* PDGF
- pneumocystis pneumonia *see* PCP
- polyethylenimine *see* PEI
- polymers 7, 61, 67, 77, 88, 169, 188, 216–17, 227
- polysaccharide nanoparticles, insulin-loaded 65
- powder formulations 54, 57, 60, 82
- propellants 70, 82–85
- protein denaturation 83
- protein therapeutics 157, 194, 207–8, 210
- proteins 45–46, 57, 59–61, 63, 65–66, 71–73, 75, 84–85, 107–8, 110–11, 200–1, 207–8, 210, 243, 251

- green fluorescent 68, 176
- plasma 27
- therapeutic 69, 194, 207, 209
- pulmonary absorption 72, 74
- pulmonary circulation 194, 196, 207
- pulmonary delivery 10, 45–46, 48, 50, 52, 54, 56, 58, 60, 76–78, 90–92, 98–100, 102, 207, 256
  - enhanced 98–99
- pulmonary diseases 12, 119, 122–23, 194, 212, 219
- pulmonary drug delivery 41, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 99–100, 125
- pulmonary ECs 195–97, 199, 202, 206, 212–14, 218
- pulmonary endothelium 193–206, 208–10, 212, 214, 216, 218, 220–22, 224–25, 228, 230, 232–33
- pulmonary gene transfer 213, 216–17
- pulmonary surfactant nanoparticles 79
- pulmonary toxicity of nanoparticles 122
  
- QDs (quantum dots) 9, 13, 24, 39, 104–6, 109–11, 118, 122, 126, 129
- quantum dots *see* QDs
- quantum dots nanoparticles 126, 129
  
- radiographic imaging 115, 121
- reactive oxygen species *see* ROS
- respiratory diseases 10, 98, 167, 169, 182, 257, 259, 269
- respiratory epithelial cells 125, 253
- respiratory syncytial virus *see* RSV
- ROS (reactive oxygen species) 24, 28–29, 32, 39, 187, 208
  
- RSV (respiratory syncytial virus) 68, 92, 168, 175–76, 185, 190, 192, 240, 247–48
- RSV infection 184–85
  
- SALP (stabilized antisense-lipid particles) 214
- severe asthma 253, 255
- smooth muscle cells 71, 237–38, 252–53
  - muscarinic receptors of 237–38
- sodium glycocholate 56–57, 64, 74
- spleen 26, 141, 145, 216, 266–67
- sputum 108–9, 117–18, 120
- stabilized antisense-lipid particles *see* SALP
- subcutaneous injections 72, 79–80, 179
- surface antigens 196
- surfactant nanoparticles 99
- surfactants 71–75, 79–80, 188
- suspensions 54–55, 58–59, 81, 84
- systemic administration 16, 26–27, 92, 231
- systemic side effects 140–41
  
- T cell receptor *see* TCR
- T-cells 156, 241
- targeted delivery 4, 6, 46, 74, 92, 107, 113, 145, 168, 191, 193–202, 204–10, 214, 218–20, 222–24
- targeted nanoparticles 14, 160
- TCNs (Thiolated chitosan nanoparticles) 64, 184
- TCR (T cell receptor) 145–46, 151, 158, 165
- tetanus toxoid *see* TT
- TGF (transforming growth factor) 30–31, 262
- theranostics 7–8, 12, 168
- therapeutic agents 8, 25, 46, 67, 77, 159, 194, 199–200, 203–04, 207, 268

- therapeutic applications 101, 124, 206–7, 209, 211, 213, 215, 217, 260
- therapeutic drugs 7, 24, 27–28, 168
- therapeutic effects 17–18, 20, 28, 32, 161, 168, 172–73, 175, 177, 195, 199, 206
- therapeutic strategies 132, 145–46, 260
- therapeutics 36, 40, 67, 103–4, 160, 162, 165, 194–95, 199, 201, 207, 219, 250, 252
- thiolated chitosan nanoparticles *see* TCNs
- TLRs (toll-like receptors) 143, 239, 241
- TNF (tumor necrosis factor) 20, 26, 120, 129
- toll-like receptors *see* TLRs
- toxicity 9, 24, 42, 68, 152, 172, 177–78, 213–17, 219, 248, 250–51, 262–63, 270
- nanoparticle-mediated 28–29
- toxicity of nanoparticles 28
- trachea 1, 70, 73
- transcription factors 139–40, 157, 228
- transcytosis 48–49, 70, 72, 203–4, 225
- transfection 212–13, 215, 217
- transfection efficiency 88, 90–91, 176, 213, 215–16, 256
- transforming growth factor *see* TGF
- transgene expression 90, 212, 215–16, 218, 233
- treatment strategies, potential nanoparticle-based 138
- treatment strategies for asthma 139, 141, 143
- triglycerides 173–74
- TT (tetanus toxoid) 63–64, 96
- tuberculosis 119–20, 132–33
- tumor cell surface 18–19
- tumor cells 18–19, 36, 107, 149, 163, 223
- tumor necrosis factor *see* TNF
- tumor tissues 18–20, 145
- tumors 16, 19, 22, 24–26, 29, 35–36, 39–40, 131, 144, 153, 176, 214, 219, 232
- solid 21, 36
- ultrafine carbon 249, 256
- ultrasound 24, 197
- vaccination 143–44, 182, 186, 247
- vaccines 45–46, 66–67, 86–87, 92, 96–97, 100–1, 157, 175, 182, 184, 188, 191, 247, 253
- nanoparticle-based 156
- vascular endothelial growth factor *see* VEGF
- vasculature 37, 69, 144–45, 154
- vectors 89–90, 195, 204, 217
- nonviral 68, 88, 176, 212
- VEGF (vascular endothelial growth factor) 22, 69, 144
- viral vectors 46, 68, 88, 212, 217–18, 225
- water 74, 79, 126, 170–71, 177, 179, 188, 216